Latest revenue
$1.14B
as of 2026-03-31
Latest net income
$278.4M
as of 2026-03-31
Net margin
24.4%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $44.12B
- Enterprise value
- $44.90B
- P/E (trailing)
- 41.6×
- Forward P/E
- —
- P/B
- 28.26×
- Dividend yield
- 0.0%
- 52-wk high
- $769.98
- 52-wk low
- $504.56
- Beta
- —
- Shares out
- 78.9M
5-year trend
What this company does
ITEM 1. BUSINESS COMPANY OVERVIEW IDEXX was incorporated in Delaware in 1983. We develop, manufacture, and distribute products and provide services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. We also provide human medical point-of-care and laboratory diagnostics. Our primary products and services are: •Point-of-care veterinary diagnostic products, comprised of instruments, consumables, and rapid assay test kits; •Veterinary reference laboratory diagnostic and consulting services; •Practice management and diagnostic imaging systems and services used by veterinarians; •Health monitoring, biological materials testing, laboratory…
AI summary unavailable — showing raw filing excerpt
Generated from IDXX's filing dated 2024-02-22
Key risks
ITEM 1A. RISK FACTORS You should consider carefully the risks and uncertainties described below in addition to the other information included or incorporated by reference in this Annual Report on Form 10-K in evaluating our company and our business. Our future operating results involve a number of risks and uncertainties, and actual events or results may differ materially from those discussed in this Annual Report on Form 10-K. Factors that could cause or contribute to such differences include, but are not limited to, the factors discussed below, as well as those factors discussed elsewhere herein. Any of these factors, in whole or in part, could materially and adversely affect our…
AI summary unavailable — showing raw filing excerpt
Generated from IDXX's filing dated 2024-02-22
Profitability
Gross margin
61.8%
1.2%Operating margin
31.6%
9.2%Net margin
24.6%
8.1%Return on equity
66.0%
18.6%Return on assets
31.6%
17.3%Leverage
Debt / equity
1.09×
2.1%Long-term debt / equity
0.23×
17.2%Debt / assets
52.1%
1.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $1.14B | +14.3% | $278.4M | +14.7% | 24.4% |
Q4 2025 2025-12-31 | $1.09B | +14.3% | $248.2M | +14.8% | 22.8% |
Q3 2025 2025-09-30 | $1.11B | +13.3% | $274.6M | +17.9% | 24.8% |
Q2 2025 2025-06-30 | $1.11B | +10.6% | $294.0M | +44.6% | 26.5% |
Q1 2025 2025-03-31 | $998.4M | +3.6% | $242.7M | +3.0% | 24.3% |
Q4 2024 2024-12-31 | $954.3M | — | $216.1M | — | 22.7% |
Q3 2024 2024-09-30 | $975.5M | +6.6% | $232.8M | +9.7% | 23.9% |
Q2 2024 2024-06-30 | $1.00B | +6.4% | $203.3M | -9.3% | 20.3% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
In Vitro & In Vivo Diagnostic Substances · SIC 2835
Your notes
Keep private notes on IDXX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$70.8M
Net activity
−$70.8M
Distinct insiders
8
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns IDXX
Institutional value
$15.93B
Total shares held
29.4M
Distinct holders
746
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 5.2M | $2.91B | — | New |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.9M | $2.20B | — | New |
| 3 | Invesco Ltd. | 1.7M | $942.9M | — | New |
| 4 | Bank of New York Mellon Corp | 1.5M | $845.4M | — | New |
| 5 | BLAIR WILLIAM & CO/IL | 946.3K | $531.7M | — | New |
| 6 | PRINCIPAL FINANCIAL GROUP INC | 881.2K | $495.2M | — | New |
| 7 | Legal & General Group Plc | 650.8K | $365.7M | — | New |
| 8 | DIMENSIONAL FUND ADVISORS LP | 573.3K | $322.1M | — | New |
| 9 | VANGUARD FIDUCIARY TRUST CO | 460.7K | $258.8M | — | New |
| 10 | Nuveen, LLC | 445.8K | $250.5M | — | New |
| 11 | AustralianSuper Pty Ltd | 443.0K | $248.9M | — | New |
| 12 | DEUTSCHE BANK AG\ | 388.8K | $218.5M | — | New |
| 13 | CIBC Bancorp USA Inc. | 367.5K | $206.5M | — | New |
| 14 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 351.6K | $197.6M | — | New |
| 15 | MONTRUSCO BOLTON INVESTMENTS INC. | 342.1K | $186.7M | — | New |
| 16 | UBS Group AG | 305.2K | $171.5M | — | New |
| 17 | Pictet Asset Management Holding SA | 287.9K | $161.8M | — | New |
| 18 | Williams Jones Wealth Management, LLC. | 263.5K | $148.1M | — | New |
| 19 | Railway Pension Investments Ltd | 256.5K | $144.1M | — | New |
| 20 | TD ASSET MANAGEMENT INC | 236.5K | $132.9M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once IDXX's latest filing finishes processing.